Navigation Links
Ikaria® Launches Next-Generation Drug-Delivery System
Date:4/11/2011

CLINTON, N.J., April 11, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced the introduction of its next-generation drug-delivery system, the INOMAX DSIR, in neonatal intensive care units (NICUs) within hospitals throughout the United States.  The INOMAX DSIR recently has been launched in Canada and Australia.

The INOMAX DSIR is a proprietary drug-delivery system that delivers the drug, INOMAX® (nitric oxide) for inhalation, the only drug approved by the U.S. Food and Drug Administration (FDA) to treat hypoxic respiratory failure (HRF) associated with pulmonary hypertension in term and near-term infants, which includes infants born at a gestational age of at least 34 weeks.  HRF is a serious condition in which blood vessels in the lungs constrict, making it difficult to oxygenate blood.  INOMAX relaxes pulmonary blood vessels, improves oxygenation and treats HRF in this delicate newborn population.

Ikaria continually develops new technologies to improve upon its existing drug-delivery systems.  The third-generation INOMAX DSIR, which has been in development since 2008, is an advance over the second-generation INOMAX DS and the early-generation INOvent® drug-delivery systems.

The INOMAX DSIR utilizes infrared technology to link the device and cylinder allowing expanded informatics on use of INOMAX therapy.  The INOMAX DSIR, like the INOMAX DS, is constructed for ease of use and contains multiple back-up warnings and alarm features to ensure the safe, consistent and reliable delivery and monitoring of INOMAX. With its compact size and weight, the INOMAX DSIR offers improved system management, such as drug usage tracking and various reminders to assist in the proper administration of INOMAX therapy.  Like the INOMAX DS, the INOMAX DSIR is compatible with more than 45 makes of ventilation devices and anesthesia machines to offer flexibility of use with patients at many ventilator settings.

"The launch of the INOMAX DSIR represents Ikaria's commitment to continually advance the technology of our delivery systems so that clinicians can safely and effectively deliver INOMAX to critically ill patients," said Daniel Tasse, Chairman and Chief Executive Officer of Ikaria.  "It is our goal to continue to meet the current and future needs of our customers with our clinically important drug, INOMAX, our ever-evolving, technologically advanced drug-delivery systems, and our one-of-a-kind technical and service support offering."  

The INOMAX DS and INOMAX DSIR drug-delivery systems are part of a comprehensive offering known as the INOMAX therapy package.  In addition to use of Ikaria's proprietary, FDA-cleared drug-delivery systems, the INOMAX therapy package includes INOMAX (nitric oxide) for inhalation, distribution, emergency delivery, technical and clinical assistance, quality maintenance, on-site hospital training, 24/7/365 customer service, and all related disposable items.

About INOMAX®  INOMAX® is a vasodilator, which, in conjunction with ventilator support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOMAX may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, and therefore may cause airway inflammation and damage. Methemoglobin, NO2, and FiO2 should be monitored during nitric oxide administration.  

Please see prescribing information.  For additional information about INOMAX, please visit www.inomax.com.  

About Ikaria, Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is pursuing a number of new indications with INOMAX. Ikaria's late stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1; as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The company also has a number of investigational compounds in development.  Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com. Company Contact:Media Contacts:Samina Bari

Tiberend Strategic Advisors, Inc.Ikaria, Inc.

(212) 827-0020(908) 238-6372Tamara Bright/Claire Sojdasamina.bari@ikaria.comtbright@tiberend.comcsojda@tiberend.com
'/>"/>

SOURCE Tiberend Strategic Advisors, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference
2. Ikaria® Names New Chief Financial Officer
3. UrgentRx® Launches Innovative Line of Portable Life-Saving Medications Across Iowa
4. Creating a Road Map for Successful Metabolic New Product Launches
5. The MED Group Launches the New National Orthotics & Prosthetics Network
6. HealthWarehouse.com Launches Application of Google Commerce Search for Prescription Medications
7. Life Spine® Announces Two New Product Launches at the 2011 American Association of Neurological Surgeons (AANS) Annual Meeting
8. Life Extension® Launches New Product Containing ChromaDexs pTeroPure® Pterostilbene
9. Generex Launches New Corporate Website
10. Berg Diagnostics Launches Molecular Diagnostics Services and Products at American Association for Cancer Research (AACR) 102nd Annual Meeting
11. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):